Expert overviews


 
What’s new in hypoglycemia from EASD 2020?
 
41
Introduction
199
Real world estimates of severe hypoglycemia (SH) and healthcare utilisation
533
Electrophysiological consequences in people with type 1 diabetes and impaired awareness of hypoglycemia
792
Hypoglycemia and driving in insulin-treated diabetes
1007
Hypoglycemia risk during flying: evaluation of safety of pilots with insulin-treated diabetes
 
 
Current guidelines for the treatment of T2DM: should metformin still remain the first line therapy in all patients with T2DM?
 
41
Current guidelines for the treatment of T2DM: should metformin still remain the first line therapy in all patients with T2DM?
483
ESC vs EASD/ADA-guidelines on diabetes and cardiovascular disease: Same evidence but different interpretations - who’s right?
 
 
Time in Range
 
338
Derived time-in-range is associated with MACE in type 2 diabetes: data from the DEVOTE trial
587
Increased time in range and sustained Auto Mode use in 670G hybrid closed-loop system users: real world experience in DIABETER
821
Chronic complications versus glycaemic variability, time in range and HbA1c in people with type 1 diabetes: sub study of the RESCUE-trial
 
 
25 years of advancement of psychosocial research and practice in diabetes
 
33
25 years of psychosocial research in diabetes
224
Contributions of psychosocial research to the understanding and integration of the social context of diabetes in care
361
Psychosocial aspects of diabetes technology
 
 
COVID-19 and diabetes
 
36
Overview on COVID-19 in persons with diabetes: What is the evidence?
257
What have we learned from COVID-19 persons with type 1 diabetes?
425
COVID-19 and type 2 diabetes: Do shared pathways have therapeutic implications?
 
 
 
 
DIABETES IN PRIMARY CARE & DIABETES EDUCATION
 
40
Position Statement by Primary Care Diabetes in Europe
377
Diabetes in Primary Care
740
Diabetes Education